HC Wainwright Has Positive Outlook for TARA Q4 Earnings
HC Wainwright has increased its Q4 2025 EPS estimates for Protara Therapeutics, now expecting ($0.32) per share, up from ($0.36). The firm maintains a "Buy" rating with a $23.00 price target. Protara's stock opened at $7.56, with a market cap of $291.72 million. Analysts have a "Moderate Buy" rating, but Weiss Ratings issued a "sell" rating. Institutional investors own 38.13% of the stock. Protara is advancing therapies for cancer and rare diseases, with its lead program TARA-002 in Phase II trials.
Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - HC Wainwright upped their Q4 2025 earnings per share (EPS) estimates for shares of Protara Therapeutics in a report released on Monday, November 24th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.32) for the quarter, up from their previous forecast of ($0.36). HC Wainwright has a "Buy" rating and a $23.00 price objective on the stock. The consensus estimate for Protara Therapeutics' current full-year earnings is ($3.32) per share. HC Wainwright also issued estimates for Protara Therapeutics' Q1 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.70) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at ($0.34) EPS.
Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Protara Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Protara Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $19.60.
Get Protara Therapeutics alerts:
Get Our Latest Analysis on TARA
Protara Therapeutics Trading Up 2.6%
TARA stock opened at $7.56 on Wednesday. The company's 50 day moving average is $5.07 and its 200 day moving average is $3.82. The stock has a market cap of $291.72 million, a price-to-earnings ratio of -4.67 and a beta of 1.59. Protara Therapeutics has a 1-year low of $2.48 and a 1-year high of $10.48.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its earnings results on Monday, November 10th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.08.
Institutional Trading of Protara Therapeutics
A number of institutional investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC bought a new stake in Protara Therapeutics during the 2nd quarter valued at $47,000. Velan Capital Investment Management LP increased its position in shares of Protara Therapeutics by 5.6% in the first quarter. Velan Capital Investment Management LP now owns 1,667,800 shares of the company's stock valued at $7,105,000 after acquiring an additional 88,800 shares during the period. Walleye Capital LLC raised its stake in shares of Protara Therapeutics by 3.9% during the first quarter. Walleye Capital LLC now owns 229,454 shares of the company's stock valued at $977,000 after acquiring an additional 8,640 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in shares of Protara Therapeutics during the first quarter worth about $64,000. Finally, American Century Companies Inc. bought a new stake in shares of Protara Therapeutics in the first quarter worth about $154,000. Hedge funds and other institutional investors own 38.13% of the company's stock.
About Protara Therapeutics
(Get Free Report)Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Read More
- Five stocks we like better than Protara Therapeutics
- What Are Earnings Reports?
- History Says These are 3 Stocks to Buy for December
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Warner Bros. Sale Rumors Heat Up: What Investors Need to Know
- 3 Small Caps With Big Return Potential
- From Science Project to Solvent: WeRide’s 761% Revenue Surge
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Protara Therapeutics Right Now?
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
